Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan To Lower Price Caps On Key Prescription Drugs

This article was originally published in PharmAsia News

Executive Summary

Japan plans new price caps on prescription drugs in April, lowered by an average of 5.2 percent. Some of the most popular drugs produced by major drug makers face an even steeper reduction in the maximum price allowed, by 10.1 percent. The new caps are expected to cause more pharmaceutical makers to shift their focus from marketing drugs in Japan to other countries. Among drugs facing the greatest price reduction are those in a new generation of medicines to lower blood pressure, including Takeda's Blopress (candesartan cilexetil), Astellas' Micardis (telmisartan) and Daiichi Sankyo's Olmetec (olmesartan). (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts